---
title: "In \"The Big Banks,\" China International Capital Corporation raised the target price for 3SBIO to 38.3 yuan with a rating of \"Buy.\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281455392.md"
description: "Bank of China International has raised the target price for 3SBIO to RMB 38.3, maintaining a \"Buy\" rating. Despite last year's performance falling short of expectations, revenue grew by 94.3% year-on-year to RMB 17.7 billion, primarily driven by RMB 9.4 billion in licensing revenue from the Pfizer authorization agreement. However, weak drug sales offset some of the growth. Excluding licensing revenue, the basic profit declined due to a decrease in gross margin and an increase in operating expenses. Pfizer plans to initiate clinical trials for SSGJ-707 in 2026, which is expected to bring milestone revenue to 3SBIO"
datetime: "2026-04-02T02:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281455392.md)
  - [en](https://longbridge.com/en/news/281455392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281455392.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281455392.md) | [繁體中文](https://longbridge.com/zh-HK/news/281455392.md)


# In "The Big Banks," China International Capital Corporation raised the target price for 3SBIO to 38.3 yuan with a rating of "Buy."

Bank of China International published a research report indicating that 3SBIO (01530.HK) performed below expectations last year, with revenue increasing by 94.3% year-on-year to RMB 17.7 billion, mainly benefiting from RMB 9.4 billion in licensing revenue contributed by Pfizer (PFE.US), partially offset by weak drug sales. Excluding licensing revenue, the basic profit declined due to a decrease in gross margin and an increase in operating expenses.

On the other hand, SSGJ-707, positioned by Pfizer as a cornerstone product for the next generation of immuno-oncology, is being monitored as Pfizer has initiated and plans to conduct related clinical trials in 2026, with expectations that the company will receive milestone revenue from Pfizer.

The firm raised the target price for 3SBIO from RMB 38.2 to RMB 38.3, maintaining a "Buy" rating

### Related Stocks

- [3SBIO (01530.HK)](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/en/news/281054154.md)
- [3SBio Proposes Spinoff, Hong Kong Listing of Unit Mandi](https://longbridge.com/en/news/266844070.md)
- [Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug](https://longbridge.com/en/news/281480931.md)
- [Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors](https://longbridge.com/en/news/281219504.md)
- [3SBio Seeks HK$3.12 Billion via Share Sale](https://longbridge.com/en/news/268172267.md)